SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda(R) have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8.
Two of the abstracts include data from the XeNA (Xeloda in NeoAdjuvant) trial, a study of Xeloda and docetaxel with or without Herceptin in patients with invasive breast cancer. The third presentation highlights findings that validate efficacy and cost benefits of Xeloda in breast cancer patients.
-- Poster No. A54, [General Poster Session A, Sept. 7, 12:00 - 12:45
p.m.], "Frequency of circulating tumor cells (CTCs) in an open-label
study of neoadjuvant capecitabine, docetaxel and trastuzumab (CDT)
combination therapy in patients with HER2+ breast cancer (BC)."
(Presenter: Stefan Gluck)
-- Poster No. 100, [General Poster Session C, Sept. 8, 7:00 - 8:00 a.m.],
"Distribution of p53 mutations by AmpliChip assay in patients receiving
neoadjuvant capecitabine (C) plus docetaxel (D) with or without
trastuzumab (T) for newly diagnosed breast cancer (BC)." (Presenter:
-- Poster No. A41, [General Poster Session D, Sept. 8, 11:45 a.m. - 12:45
p.m.], "Capecitabine is associated with fewer adverse events than other
standard therapies in patients with breast cancer: a claims database
analysis." (Presenter: Hope Rugo, M.D.)
These studies affirm Roche's commitment to exploring the expanded use of Xeloda in combination with new therapies.
Xeloda is the only FDA-approved oral chemotherapy for both metastatic
breast cancer and adjuvant and metastatic colorectal cancer. Inactive in
pill form, Xeloda is enzymatically activated within the body; when it comes
into contact with a naturally occurring protein called thymidine
phosphorylase, or TP, Xeloda is transformed into
Copyright©2007 PR Newswire.
All rights reserved